- Open Access
The aftermath of the Merck's HIV vaccine trial
- Enrico Iaccino†1,
- Marco Schiavone†2,
- Giuseppe Fiume†1,
- Ileana Quinto1, 2 and
- Giuseppe Scala1, 2Email author
© Iaccino et al; licensee BioMed Central Ltd. 2008
- Received: 17 April 2008
- Accepted: 02 July 2008
- Published: 02 July 2008
The recently released results of the Merck's Phase IIb "test-of concept" vaccine trials have shown no protection from HIV-1 infection in the vaccinated group compared with a control group vaccinated with placebo. The study was designed to test the Merck's MRKAd5 trivalent candidate vaccine. The vaccine formulation was expected to stimulate a HIV-specific T cell immune response and to either prevent infection, or to reduce the levels of the viral load in vaccinated subjects. Upon the first evaluation of the interim data, the independent Data and Safety Monitoring Board (DSMB) underscored no protection from HIV-1 infection in the vaccine-inoculated volunteers compared with the control group; accordingly, the vaccine trial was stopped. This disappointing outcome warrants a critical analysis of the current vaccine studies and calls for a renewed effort toward a rational design of novel immunogens to be tested in large primate trials.
- Vaccine Trial
- Escape Mutant
- Viral Reservoir
- Plasma Viremia
- Infection Drug User
Rates of HIV-1 infections in the vaccinees and in placebo inoculated volunteers enrolled in the STEP vaccine trial.
No immunity to Ad5 (< 18 units)
immunity to Ad5
High immunity to Ad5
Very high immunity
to Ad5 (> 1000 units)
out of 382 total
out of 140 total
14 infected out of
7 infected out of 163
20 infected out
of 394 total
out of 142 total
7 infected out of 229
2 infected out of 157
Antibody-mediated immune response is elicited after few weeks from primary infection; however, the anti-HIV antibodies show a poly-specificity for non-neutralizing, linear epitopes . Antibodies specific for conserved, conformational epitopes are elicited at later stage and may play a favorable role by decreasing the plasma viremia [16–18]. In addition, anti-HIV envelope antibodies also contribute to the containment of infected T cells by triggering antibody-mediated cell cytotoxicity (ADCC; ). As in the case of virus escape mutants promoted by the T-cell immune pressure, escape mutants are generated in presence of epitope specific antibodies .
In this setting, most vaccine trials in humans have been initiated under the assumption that the immune response to HIV-1 differs from the one elicited in non-human primates upon infection with SIV or SHIV strains; by inference, only vaccine trials in humans would validate vaccine candidates. Consistently, a large number of monkey vaccine studies have been overlooked despite the evidence that the monkeys' models of SIV/SHIV infection mimic well the natural HIV-1 infection in human subjects. Indeed, monkeys infected with SIV or SHIVs show levels of viremia comparable with the ones experienced by HIV-infected subjects in the course of the primary infection and at the subsequent set points [21, 22]; CD4 activated T cells are the main susceptible cell type and the involved anatomical districts, mucosal sites and lymphoid tissues, are similar ; the functional characteristics of the monkeys' immune response do not differ significantly from the one elicited in humans both at the time of primary infection and at the later stage of the immune deficiency [13, 23]; the T cell-mediated and the antibody immune response are comparable with the ones elicited in humans infected with HIV-1 strains and give rise to escape viral mutants, as reported in HIV-1 infected subjects [12, 23, 24]. Relevant to the vaccine field, several monkey studies have documented that passive transfer of neutralizing MAbs induced protection from systemic and mucosal challenge [25–27]. This evidence indicates a narrow path to a successful HIV vaccine based on the induction of neutralizing antibodies focused on conserved, constrained envelope domains.
The results coming from previous studies in monkeys, including the ones promoted by Merck in collaboration with academic laboratories, may have been largely ignored. For example consider the world's first 2 phase 3 of HIV-1 vaccine efficacy trials that involved two large cohorts of HIV-1-uninfected volunteers and were completed in 2003 . The first trial (VAX004) included 5403 individuals from North America and The Netherlands; the cohort included both men who have sex with men and 308 women at high risk for heterosexual transmission. The second trial (VAX003) was conducted in 2527 infection drug users subjects in Thailand [29, 30]. Both the studies relied on recombinant gp120 envelope protein as the vaccine immunogen. Results from both the studies indicated that despite a robust antibody response elicited in vaccinees, no significant protection from HIV-1 infection was detected in the placebo and in the vaccine inoculated groups . These negative results were anticipated by monkeys studies designed to test a variety of envelope proteins as anti-HIV immunogens . Among these pre-clinical studies, the 2001 work of Cho et al.  analyzed the efficacy of mono- or polyvalent envelope proteins from distinct HIV clade B strains. This study reported that despite the induction of a strong anti-envelope antibody in vaccinated monkeys, no significant protection from the SHIV challenge was detected .
In the case of the Merck's STEP HIV vaccine trial, the rationale was based on a preclinical vaccine study in rhesus macaques monkeys (Macaca mulatta) primed with a plasmid expression vector followed by a boost with Ad5, a replication-incompetent adenoviral vaccine vector, which both delivered the SIVmac239 gag gene; the monkeys were then challenged with SHIV-89.6P, a pathogenic strain . The reported results showed high levels of CD8+ T-cell response by tetramer staining at around week 35 post-challenge and a preserved CD4 T-cells up to day 180. Peak viremia was in the range of 106–107 at about week 3, one log lower than the naïve animals; animals were followed up to 120 days . In a distinct study, Barouche et al. reported the case of a monkey immunized with a plasmid expressing SIV gag plus IL2-Ig protein and challenged with pathogenic SHIV89.6P ; this animal, which showed low levels of plasma viremia at week 10–20, developed an escape mutant of the Gag p11C immunodominant epitope and showed a rapid disease progression and death from AIDS-related syndrome . These reports are fully consistent with the dynamics of immune escape of HIV in infected subjects [4, 17] and highlight the need for a vaccine capable of inducing a drastic decrease of the viremia at the primary infection to prevent the development of pathogenic escape mutants and the impairment of the T-cell repertoire.
These representative studies raise the question of the quality and the extent of the induced immune response. Indeed, both in monkeys and in human vaccine trials, positive results were expected from the presence of either a strong anti-envelope antibody response , or a robust T-cell mediated immunity . Clearly, the main correlates of protection, anti-envelope antibodies and T-cell induced activation, need to be re-evaluated. In the case of the antibody response, previous studies have assessed the specificities and concentrations of neutralizing Abs required to achieve a complete protection from systemic or mucosal infection [25, 26]; however, the major challenge in the field is to devise novel immunogens to induce antibodies that match the epitope specificities and affinity of the few available neutralizing antibodies . In the HIV vaccine field, the T cell-mediated immune response is assessed by ELISPOT and polychromatic FACS analysis to detect cytokine-expressing cells  without a functional assessment of T-cell killing activity toward HIV-infected cells. Thus, the functional parameters of successful T-cell activities are still missing and may hamper the predictive value of the ongoing phase 1–2 immunogenicity studies [37–39].
In the context of the above-mentioned studies, clinical trials have flourished upon societal and economic pressure from geographic regions heavily affected by AIDS, and fueled by a large financial support from public and private institutions [40, 41]. However, vaccine trials with the available immunogens in different vector systems may, at best, only moderately decrease the levels of plasma viremia and are not expected to improve the protection from infection. Likewise, any trial with a suboptimal immunogen in a high HIV incidence areas may create a significant number of vaccine breakthroughs and would raise ethical and financial issues concerning the treatment of the infected volunteers . In this context, we should learn from the STEP trial that preclinical studies in monkeys are feasible and may anticipate future results in human subjects. Preclinical studies in non-human primates should be expanded in terms of number of animals, study designs to assess potential negative effects and length of the post-challenge follow-up. Several lessons are coming form the Merck vaccine study:
a. A vaccine aimed at inducing T-cell immunity will not prevent primary infection and the establishment of the viral reservoir;
b. Studies aimed at inducing neutralizing antibodies should be pursued with even greater efforts toward a rational development of structurally defined conformational epitopes, and tested in suitable monkey models;
c. The host immune system will react to both the vector and the immunogen in an unpredictable way, by activating a complex immune response that includes the innate and the epitope-specific immunity;
d. Studies aimed at modeling human behavior in the context of HIV exposure during vaccination should be developed and used to test for potential vaccine-induced enhancement of infection.
The STEP vaccine has not provided a successful road to an effective HIV vaccine; however, it has shown to us that we still know too little and should learn more.
The authors would like to acknowledge M. Lewis for helpful discussions and suggestions.
This work was supported by grants from the Italian National Institute of Health, FP6-EU grant EPIVAC and FP7-EU grant EUROPRISE.
- Press Releases – HIV Vaccine Trials Network. [http://www.hvtn.org/media/pr/step111307.html]
- Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M: Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005, 434: 1093-1097.View ArticlePubMedGoogle Scholar
- Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B: HIV-1 latency in actively dividing human T cell lines. Retrovirology. 2008, 5: 37.PubMed CentralView ArticlePubMedGoogle Scholar
- Schiavone M, Quinto I, Scala G: Perspectives for a protective HIV-1 vaccine. Adv Pharmacol. 2008, 56: 423-452.View ArticlePubMedGoogle Scholar
- Wu Y: HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology. 2004, 1: 13.PubMed CentralView ArticlePubMedGoogle Scholar
- Marcello A: Latency: the hidden HIV-1 challenge. Retrovirology. 2006, 3: 7.PubMed CentralView ArticlePubMedGoogle Scholar
- Sun Y, Permar SR, Buzby AP, Letvin NL: Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. J Virol. 2007, 81: 8009-8015.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT: Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005, 434: 1148-1152.PubMedGoogle Scholar
- Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS: Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy. J Infect Dis. 2008, 197 (5): 714-720.View ArticlePubMedGoogle Scholar
- Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sékaly RP, McMichael AJ, Pantaleo G: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001, 410: 106-111.View ArticlePubMedGoogle Scholar
- Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 2002, 415: 335-339.View ArticlePubMedGoogle Scholar
- Barouch DH, Letvin NL: HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines?. Lancet. 2004, 364: 10-11.View ArticlePubMedGoogle Scholar
- Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, Cohen OJ, vanCott TC, Iwanicki M, Lewis MG, et al: Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med. 2001, 7: 1225-1231.View ArticlePubMedGoogle Scholar
- Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S: Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003, 77: 11708-11717.PubMed CentralView ArticlePubMedGoogle Scholar
- O'Connor DH, Burton DR: Immune responses and HIV: a little order from the chaos. J Exp Med. 2006, 203: 501-503.PubMed CentralView ArticlePubMedGoogle Scholar
- Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA. 2003, 100: 4144-4149.PubMed CentralView ArticlePubMedGoogle Scholar
- Loh L, Petravic J, Batten CJ, Davenport MP, Kent SJ: Vaccination and timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog. 2008, 4: e12.PubMed CentralView ArticlePubMedGoogle Scholar
- Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, Little SJ, Richman DD: Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol. 2005, 79: 6523-6527.PubMed CentralView ArticlePubMedGoogle Scholar
- Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR: Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007, 449: 101-104.View ArticlePubMedGoogle Scholar
- Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Robinson JE, Shaw GM: Antibody neutralization and escape by HIV-1. Nature. 2003, 422: 307-312.View ArticlePubMedGoogle Scholar
- Busch M, Abel K, Li J, Piatak M, Lifson JD, Miller CJ: Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge. Vaccine. 2005, 23: 4036-4047.View ArticlePubMedGoogle Scholar
- Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, Vajdy M: Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Aids. 2008, 22: 339-348.View ArticlePubMedGoogle Scholar
- Barouch DH, Kunstman J, Glowczwskie J, Kunstman KJ, Egan MA, Peyerl FW, Santra S, Kuroda MJ, Schmitz JE, Beaudry K, Krivulka GR, Lifton MA, Gorgone DA, Wolinsky SM, Letvin NL: Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol. 2003, 77: 7367-7375.PubMed CentralView ArticlePubMedGoogle Scholar
- Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ: HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 2004, 10: 282-289.View ArticlePubMedGoogle Scholar
- Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 1999, 5: 204-210.View ArticlePubMedGoogle Scholar
- Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000, 6: 207-210.View ArticlePubMedGoogle Scholar
- Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001, 75: 8340-8347.PubMed CentralView ArticlePubMedGoogle Scholar
- Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005, 191: 666-677.View ArticlePubMedGoogle Scholar
- Berman PW: Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses. 1998, 14 (Suppl 3): S277-289.PubMedGoogle Scholar
- Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, Johnson A, Klaussen M, Prashad H, Köhne C, deWit C, Gregory TJ: Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology. 1999, 265: 1-9.View ArticlePubMedGoogle Scholar
- Rasmussen RA, Montefiori DC, Robinson HL, McClure HM, Ruprecht RM: Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. J Infect Dis. 2001, 184: 1603-1607.View ArticlePubMedGoogle Scholar
- Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA: Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol. 2001, 75: 2224-2234.PubMed CentralView ArticlePubMedGoogle Scholar
- Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002, 415: 331-335.View ArticlePubMedGoogle Scholar
- Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000, 290: 486-492.View ArticlePubMedGoogle Scholar
- Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J: Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 2007, 4: e348.PubMed CentralView ArticlePubMedGoogle Scholar
- Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW: Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007, 45: 20-27.View ArticlePubMedGoogle Scholar
- Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L, NIAID HIV Vaccine Trials Network: High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis. 2005, 192: 1249-1259.View ArticlePubMedGoogle Scholar
- Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L, National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network: Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr. 2007, 44: 203-212.PubMed CentralView ArticlePubMedGoogle Scholar
- Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008, 205: 63-77.PubMed CentralView ArticlePubMedGoogle Scholar
- HIV Vaccine Trials Network – Working to prevent AIDS. [http://www.hvtn.org]
- Global Health Program – Bill & Melinda Gates Foundation. [http://www.gatesfoundation.org/GlobalHealth]
- Koski G, Nightingale SL: Research involving human subjects in developing countries. N Engl J Med. 2001, 345: 136-138.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.